Your Health, We Care
Based on the results of the COLUMBUS clinical trial, Binimetinib was first approved for marketing in the United States on June 27, 2018.
Before starting treatment, it is necessary to identify the presence of BRAF V600E or V600K mutations in the tumor sample.
